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Neuropilin 1Recent studies have demonstrated that neuropilin 1 (NP-1) is involved in HTLV-1 entry; however, the role
NP-1 plays in this process is not understood. We demonstrated that ectopic expression of human NP-1 but
not NP-2 cDNA increased susceptibility to HTLV-1. SiRNA-mediated inhibition of NP-1 expression
correlated with signiﬁcant reduction of HTLV-1 Env-mediated fusion. The vascular endothelial growth
factor (VEGF165) caused downmodulation of surface NP-1 and inhibited HTLV-1 infection of U87 cells. In
contrast, VEGF165 partially inhibited infection of primary astrocytes and had no signiﬁcant effect on
infection of HeLa cells. VEGF165 and antibodies to the glucose transporter protein 1 (anti-GLUT-1) were
both needed to block infection of primary astrocytes, however, only anti-GLUT-1 antibodies were sufﬁcient
to block infection of HeLa cells. HTLV-1 Env forms complexes with both NP-1 and GLUT-1 in primary
human astrocytes. The alternate usage of these two cellular receptors may have important implications
regarding HTLV-1 neuro-tropism.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent
of adult T-cell leukemia/lymphoma (ATLL) and a progressive
demyelinating disease known as tropical spastic paraparesis/HTLV-1
associated myelopathy (TSP/HAM) (reviewed in Feuer and Green,
2005; Gallo, 2005; Yoshida, 2005). HTLV-1 was the ﬁrst human
retrovirus to be isolated and characterized (Gallo, 2005). Retroviral
infection is associated with a number of pathologic abnormalities,
including a variety of cancers, immunologic diseases, and neurological
disorders. ATLL is characterized by T cell oncogenesis, whereas HAM/
TSP involves cellular destruction and inﬂammation of the upper
motor neurons. ATL and HAM are the most devastating diseases
associated with HTLV-1 infection. Vaccines or cures to these diseases
are not available. While clinical symptoms of ATL and HAM are well
deﬁned, the molecular determinants involved in this differential
disease pathogenesis are unknown. This highlights the importance of
developing new strategies aimed at preventing HTLV-1 infection., wild type HTLV-1 envelope
nv63 defective in syncytium
g Medical University, Nanjing,
ll rights reserved.Manel et al. (2003) have identiﬁed the glucose transporter type 1
(GLUT-1) as a receptor for HTLV-1 and HTLV-2. The results by Manel
et al. have suggested that, in addition to GLUT-1, other cofactors/
coreceptors might be involved in HTLV-1 infection (reviewed in
Manel et al., 2005). However, the lack of a cell system that does not
express GLUT-1 hasmade it difﬁcult to provide experimental evidence
for the existence of alternative receptors or coreceptors.
The literature reported a number of observations that favor the
alternate receptor usage by HTLV-1, however, evidence for the
utilization of these receptors in primary cells is lacking. Previous
studies demonstrated that DC-SIGN facilitates fusion of dendritic cells
with HTLV-1-infected cells (Ceccaldi et al., 2006). Other studies
claimed that heparan sulfate proteoglycans (HSPGs) might play a role
in HTLV-1 entry (Jones et al., 2006, 2005; Pinon et al., 2003;
Takenouchi et al., 2007). Recent work by Lambert et al. (2009)
demonstrated an important role for NP-1 and HSPG in HTLV-1
infection of dendritic cells. Jones et al. (2008) demonstrated that
blocking interactions with either NP-1 or HSPGs decreased the
infection of CD4+ T cells. It is possible that HSPGs are utilized by
HTLV-1 in certain cell culture conditions and may have a role in viral
attachment, however, the exact contribution of HSPGs and their
relevance for the observed in vivo tropism of HTLV-1 to CD4+ T
lymphocytes remain controversial. We have previously provided
evidence for the utilization of GLUT-1 for HTLV-1 infection of CD4+ T
lymphocytes, the targets for HTLV-1 in vivo (Jin et al., 2006a). We
have also described a 5 bp deletion in the GLUT-1 gene of the
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express very low levels of GLUT-1 (Jin et al., 2006a). We have
proposed a GLUT-1-independent pathway for the observed efﬁcient
HTLV-1 infection of U87 cells (Jin et al., 2006a).
Recent studies reported neuropilin 1 (NP-1), a receptor for
Semaphorin 3A (Sema3A) and vascular endothelial growth factor, as
a co-factor for HTLV-1 (Ghez et al., 2006). NP-1 is a transmembrane
protein initially identiﬁed as an epitope recognized by a monoclonal
antibody (A5) that labels speciﬁc subsets of axons in the developing
Xenopus nervous system (Takagi et al., 1991). NP-1 is a cell surface
receptor that has been implicated to function in the development of
both the cardiovascular and nervous systems. NP-1 is a receptor for
the axonal chemo repellent semaphorin III (Sema III) (He and Tessier-
Lavigne, 1997; Kolodkin et al., 1997). Sema III is a secreted protein
that in vitro causes neuronal growth and in vivo is required for correct
sensory afferent innervations and other aspects of development. NP-1
can also bind with high afﬁnity to select isoforms of vascular
endothelial growth factor (VEGF) including VEGF165 (Soker et al.,
1998). VEGF is a highly secreted polypeptide growth factor with ﬁve
alternatively spliced isoforms of which VEGF165 and VEGF121 are the
most abundant (Neufeld et al., 1999).
In the present study, we examined the role of human NP-1 in
HTLV-1 Env-mediated fusion and HTLV-1 infection. We demonstrate
that HTLV-1 utilizes NP-1 and GLUT-1 as receptors to infect the
astroglioma/astroblastoma U87 cells and human primary astrocytes.
The results may provide important insight into HTLV-1 neuro-tropism
and pathogenesis.Fig. 1. Expression of NP-1 and GLUT-1 in primary human astrocytes and cell lines. (A and B)
text. Ampliﬁcation of β-actin was used as a control for gel loading. The data represent scan
GLUT-1 in cell lines and primary human astrocytes. Polyclonal antibodies were used to analyz
Staining of CHO was performed to provide evidence for the low expression levels of GLUT-Results
Human neuropilin 1 (NP-1) is abundantly expressed in U87 cells and
primary human astrocytes
We have previously demonstrated that HTLV-1 Env-mediated
fusion and infection of U87 cells is not sensitive to GLUT-IgY
antibodies suggesting a GLUT-1-independent pathway of viral entry
(Jin et al., 2006a). To examine GLUT-1 and NP-1 RNA expression in
U87 cells, we performed RT-PCR using freshly isolated total RNA from
U87, HeLa cells, 293 cells, or normal human astrocytes (NHA). The
results show that NHA expressed both GLUT-1 and NP-1 RNA (Fig.
1A). The expression pattern of GLUT-1 and NP-1 was different in the
cell lines. The U87 cell line expressed relatively high levels of NP-1 and
very low levels of GLUT-1 (Fig. 1B). The relative expression levels
were compared to the endogenous expression of β-actin. In contrast,
HeLa cells expressed the highest levels of GLUT-1 (Fig. 1B). The 293
cells expressed both NP-1 and GLUT-1 proteins at lower levels
compared to the NP-1 in U87 cells and GLUT-1 in HeLa cells (Fig. 1B).
We have previously demonstrated that most of HTLV-1 Env-mediated
fusion with HeLa cells can be inhibited using GLUT-IgY (Jin et al.,
2006a).
FACS analysis was performed to analyze NP-1 and GLUT-1 surface
expression. We used mouse monoclonal anti-human GLUT-1 to stain
GLUT-1 and anti-NP-1 monoclonal antibodies (Miltenyi Biotec and
R&D System) to stain cell surface NP-1. High GLUT-1 staining was
always detected on NHA and HeLa cells but only background levelsRT-PCR analysis of NP-1 and GLUT-1 mRNA expression was performed as described in
s of agarose gels stained with ethidium bromide. (C) FACS analysis of surface NP-1 and
e NP-1 expression while expression of GLUT-1 was analyzed using GLUT-IgY antibodies.
1 and NP-1 proteins.
Fig. 2. Human neuropilin 1 (NP-1) acts as a fusion receptor for HTLV-1. CHO cells were
transfected with pCNDA3 plasmids encoding either vector, rat NP-1, human NP-1,
human NP-2, GLUT-3 or GLUT1 under T7 promoter. Expression of the proteins was
accomplished by infection with vaccinia virus encoding T7 RNA polymerase. The CHO
cells expressing the different proteins were mixed with HTLV-1 Env-expressing 293
cells that co-express T7-lacZ reporter. Following incubation the extent of Env-mediated
cell fusion was quantiﬁed by measuring β-galactosidase production. The competence of
the transfected cells to undergo cell fusion was veriﬁed by VSV fusion (A). The ability of
the transfected cells to fuse with the HTLV-1 Env63 is shown in panel B. Expression of
rat and human NP-1 was veriﬁed by Western blotting using a polyclonal antibody
against the human NP-1 that cross-reacts with rat NP-1 but not with human NP-2 (C).
The results were reproduced at least four times. The control envelope Unc63 is a
cleavage mutant of HTLV-1 Env63 that does not promote cell fusion.
205Q. Jin et al. / Virology 396 (2010) 203–212detected on U87 cells (Fig. 1C). We consistently observed abundant
expression of human NP-1 in both U87 cells and NHA but almost
background levels detected on HeLa cells (Fig. 1C). Since we used CHO
cells for ectopic expression of NP-1 and GLUT-1 the CHO cells were
stained to verify the low endogenous levels of surface GLUT-1 and NP-
1 proteins (Fig. 1C). These results show differential expression of NP-1
and GLUT-1 in the four cell populations and conﬁrm our previous
observations of low levels of GLUT-1 protein expression in U87 cells
(Jin et al., 2006a).
Human NP-1 acts as a fusion receptor for HTLV-1 in transfected
CHO cells
To determine whether neuropilins could serve as HTLV-1
receptors we used CHO cells for ectopic expression of human
NP-1 or NP-2, rat NP-1, and GLUT-1 or GLUT-3 as cellular targets
in the Env-mediated fusion assay. The rationale for using CHO cells
is they express low levels of GLUT-1 and trace levels of NP-1 (Fig.
1C). The competence of the transfected targets in Env-mediated
fusion was veriﬁed by VSV fusions (Fig. 2A). The CHO cells
expressing recombinant NP-1 showed higher fusion signal than
those expressing recombinant GLUT-1 (Fig. 2B). Furthermore, the
fusion signal was signiﬁcantly higher with cells expressing
recombinant NP-1 compared to cells expressing recombinant
NP-2 (Fig. 2B). The rat NP-1 showed some activity in this assay
but was signiﬁcantly lower than the human NP-1. Low signals
above the background were observed with GLUT-3 or empty vector
transfected CHO cells (Fig. 2B). Expression of the human and rat
NP-1 proteins was veriﬁed by Western blotting using commercially
available rabbit polyclonal antibodies against human NP-1 which
cross- react with the rat NP-1 but not with the human NP-2 (Fig.
2C). The results demonstrated that human NP-1 acts as a fusion
receptor for HTLV-1.
SiRNA-mediated reduction of NP-1 protein expression blocks HTLV-1
Env-mediated fusion with U87 cells
To examine the role of NP-1 in HTLV-1 Env-mediated fusion with
U87 cells we compared the effect of reducing the expression levels of
GLUT-1 versus NP-1 by using siRNA speciﬁc to each gene. Signiﬁcant
reduction of NP-1 and GLUT-1 protein expression in siRNA-trans-
fected cells was conﬁrmed by Western blotting (Fig. 3A). The GLUT-1
gel imagewas obtained by over-exposure of the gel containing the RT-
PCR reaction since U87 express relatively low levels of GLUT-1 (Fig.
3A). The effect of siRNA on Env-mediated fusion was assayed by
measuring β-galactosidase produced as a result of mixing siRNA-
transfected target cells with HTLV-1 Env-expressing 293 cells. The
results demonstrate that NP-1 siRNA-transfected U87 cells had a
signiﬁcant reduction in their ability to fuse with HTLV-1 Env (Fig. 3B).
In contrast, GLUT-1 siRNA-transfected U87 cells (corresponding to
lane 3) were indistinguishable from control vector-transfected cells in
terms of their Env-mediated fusion signal (Fig. 3B, compare graphs
and lanes 1 and 3). The competence of the transfected cell populations
to undergo cell fusion was conﬁrmed with VSV Env-expressing cells
(Fig. 3C).
VEGF165 downmodulates NP-1 expression
NP-1 was identiﬁed as a functional receptor for VEGF165 (Soker
et al., 1998). Since VEGF165 binds with high afﬁnity to NP-1 we
examined the effect of incubating VEGF165 with U87 cells expressing
endogenous NP-1. We utilized a similar strategy to that previously
reported by Narazaki and Tosato who were the ﬁrst to provide
experimental evidence for VEGF165-induced internalization of NP-1
in endothelial cells (Narazaki et al., 2008; Narazaki and Tosato,
2006). The U87 cells were pre-incubated with or without 500 ng/mlVEGF165 and then stained with a monoclonal antibody speciﬁc to
human NP-1. This is a commercially available antibody generated
against the a1 domain of NP-1 that is distant from the well-known
VEGF165 binding site (Fig. 4A). Cell surface expression of NP-1 on
U87 cells was consistently obtained using this antibody (Fig. 4B).
Signiﬁcant reduction in cell surface expression of NP-1 with U87
cells pre-incubated with VEGF165 (Fig. 4C). This suggested that NP-1
surface expression was downmodulated by its speciﬁc ligand
VEGF165. Downmodulation of NP-1 was only observed when
antibodies distant from the VEGF165 binding site were used. To
conﬁrm these results we repeated the experiment and divided the
VEGF165-treated U87 cells into two equal portions, one was directly
incubated with the anti-NP-1 antibody (non-permeabilized); the
Fig. 3. SiRNA-mediated reduction of NP-1 expression correlates with signiﬁcant blocking of HTLV-1 Env-mediated fusion. The siRNA molecules were transfected into U87 cells and
the reduction of gene expression was veriﬁed byWestern blot analysis (A). The GLUT-1 gel was exposed ﬁve times the exposure time of the NP-1 gel (A). The transfected cells were
infected with vaccinia recombinant encoding T7 RNA polymerase and mixed with Env-expressing 293 cells expressing T7-lacZ reporter. The potency of the transfected cells to
promote HTLV-1 Env-mediated fusion was examined bymeasuring the amount of β-galactosidase produced (B). VSV Env-mediated fusionwas used as a positive control to verify the
competence of the transfected cells to undergo cell fusion (C). The numbers 1, 2 and 3 below the lanes correspond to the transfected control, NP-1 or GLUT-1 siRNA respectively. The
GLUT-1 gel images shown in panel A was over-exposed to visualize the siRNA effect in U87 cells that express low levels of GLUT-1.
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antibody treatment. The results demonstrated an increase in NP-1
staining in permeabilized cells that could account for the internal-Fig. 4. Downmodulation of human NP-1 by VEGF165. (A) Schematic diagram illustrating
the different domains of the human NP-1, the binding site of VEGF165, and the anti-NP-1
antibodies used in this analysis. The mouse anti-human BDCA-4 (Neuropilin-1)
monoclonal antibody recognizes the a1 domain of the human NP-1. (B and C) Flow
cytometry analysis of surface expression of the human NP-1 on U87 cells, pre-incubated
at 37 °C for 30min in the absence of VEGF165 (B) or in the presence of VEGF165 (C). Panel
D shows another experiment where surface expression of the human NP-1 was
analyzed in the presence of VEGF165. Following treatment with VEGF165 the U87 cells
were divided into two aliquots, one was directly stained with anti-NP-1 (non-
permeabilized); the other was treated with 0.3% Triton-X100 for 20 min at 4 °C then
stained with anti-NP-1 antibodies (permeabilized).ized NP-1 (Fig. 4D). This suggests receptor downmodulation as a
potential mechanism for the observed antiviral activity of VEGF165.
HTLV-1 infection of primary astrocytes and U87 cells is sensitive
to VEGF165
VEGF165-induced speciﬁc downmodulation of NP-1 suggested
that VEGF165 may compete with HTLV-1 Env for binding to NP-1.
To conﬁrm this we added recombinant VEGF165 at increasing
concentrations to U87 cells or NHA then infected them with HTLV-
1 pseudotyped virus. We found that VEGF165 speciﬁcally inhibited
HTLV-1 infection of both U87 cells (Fig. 5A) and NHA primary
astrocytes (Fig. 5B). We consistently observed more potent
VEGF165 inhibitory effect in U87 cells (Fig. 5A) than in NHA
primary astrocytes (Fig. 5B). Since the VEGF165 source was
bacterial, we used similar concentrations of an afﬁnity-puriﬁed
CC chemokine MIP-1β puriﬁed from bacteria as a negative control.
This control protein had no signiﬁcant effect on HTLV-1 infection
of either U87 cells (Fig. 5A) or NHA primary astrocytes (Fig. 5B).
GLUT-IgY or the control IgY antibodies also had no signiﬁcant
effect on HTLV-1 infection of U87 cells (Fig. 5C). In contrast, GLUT-
IgY but not the control IgY antibodies caused signiﬁcant inhibition
of infection of primary astrocytes (Fig. 5D). These results
demonstrate that HTLV-1 utilizes NP-1 as a major receptor for
entry into U87 cells but uses both GLUT-1 and NP-1 for entry into
NHA primary astrocytes.
Alternate receptor usage of NP-1 and GLUT-1
The observed potent VEGF165 inhibition of HTLV-1 Env fusion with
U87 cells prompted us to analyze whether NP-1 and GLUT-1 are both
utilized for HTLV-1 entry in NHA. We reasoned that if GLUT-1 were
utilized as a major receptor then the VEGF165 would have little or no
effect on HTLV-1 entry. We used GLUT-IgY to block GLUT-1-mediated
infection (Jin et al., 2006a, 2006b) and VEGF165 to block NP-1-
mediated infection. The HTLV-1 pseudotyped virus infection of NHA
was sensitive to both GLUT-IgY and VEGF165 (Fig. 6A). The blocking
activitywas consistently higherwith GLUT-IgY than VEGF165 (Fig. 6A).
However, when used together the blocking effect was enhanced (Fig.
6A). The VEGF165 alone had efﬁcient blocking effect on infection of
U87 cells while GLUT-IgY had little effect (Fig. 6B). In contrast,
infection of HeLa cells was efﬁciently blocked by GLUT-IgY but was
insensitive to VEGF165 (Fig. 6C). The results suggested that GLUT-1
Fig. 5. VEGF165 blocks HTLV-1 infection of U87 cells and primary human astrocytes. To examine NP-1-mediated infection the commercially available VEGF165 or IL-2 were added to
the indicated cell populations at escalating concentrations and incubated for 1 h at 37 °C before infection with the pseudotyped HTLV-1 virus (A and B). To examine the effect of
GLUT-1-mediated infection other portions of the same cell populations were incubated with escalating doses of either GLUT-IgY or control IgY antibodies before HTLV-1 infection
(C and D). Seventy-two hours post-infection, the cells were lysed and infectivity measured by the amount of luciferase produced (RLU). Unc63 is a control with a mutated envelope
protein that is defective in membrane fusion. IL-2 was used as a negative control for the VEGF165 activity. The control for GLUT-IgY activity was the normal chicken IgY. This
experiment was reproduced at least three times.
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primary astrocytes but only one receptor is utilized in HeLa or U87 cell
lines.
Physical interaction of HTLV-1 Env with human NP-1 and GLUT-1
proteins in normal human astrocytes
Previous studies have demonstrated physical interaction of HTLV-
1 Env, NP-1 and GLUT-1 in 293 cells (Ghez et al., 2006). To
demonstrate this interaction in primary astrocytes we infected NHA
(endogenous NP-1 and GLUT-1) with either an empty vaccinia virus
vector (WR) or a recombinant vaccinia virus encoding the Env63.
Total cell lysates were used for immunoprecipitation with anti-NP-1
antibodies. The immunoprecipitated proteins were analyzed in
immunoblots that have been reacted with antibodies to either
GLUT-1 or HTLV-1 Env. As expected, probing the blot with anti-NP-
1 antibodies detected the NP-1 protein in both the control and Env63-
expressing NHA with more NP-1 protein detected in the presence of
Env63 (Fig. 7A). The higher molecular weight (MW) protein band
seen above the NP-1 band may represent protein oligomers.
Immunoblotting with anti-Env monoclonal antibodies detected the
soluble subunit gp46 protein band with no bands detected in the
controlWR lane (Fig. 7B). Immunoblotting with anti-GLUT-1 antibody
revealed the GLUT-1 protein bands in both NHA cell samples
expressing either controlWR vector or Env63 (Fig. 7C). This suggestedthe physical association of NP-1 and GLUT-1 proteins without the
presence of HTLV-1 Env. Higher molecular weight bands were
detected in the Env-63-expressing cells but not in the control (Fig.
7C). The high MW protein bands detected in all three panels might
represent incompletely denatured protein complexes between Env,
NP-1 and GLUT-1. The results demonstrate physical interaction
between HTLV-1 Env, NP-1, and GLUT-1 in primary human astrocytes.Discussion
This study utilized three cellular models to show that GLUT-1 and
NP-1 can serve as cellular receptors for HTLV-1. HTLV-1 exclusively
utilizes human NP-1 as a cellular receptor to infect the astroglioma/
astroblastoma U87 cell line that expresses low levels of cell surface
GLUT-1 (Jin et al., 2006a). In contrast, HTLV-1 strictly utilizes GLUT-1
on HeLa cells as a cellular receptor despite the observed low
expression levels of NP-1. Interestingly, HTLV-1 utilizes both GLUT-1
and NP-1 to infect human primary astrocytes. This conclusion is based
on the observed additive blocking effect by GLUT-IgY and VEGF165,
two reagents that bind to GLUT-1 andNP-1 respectively. The optimum
number of receptor molecules required for HTLV-1 entry is currently
unknown.We hypothesize that the relative expression levels of GLUT-
1 and NP-1 proteins might determine the choice of their utilization by
HTLV-1.
Fig. 6. HTLV-1 Infection of primary human astrocytes is sensitive to both VEGF165 and anti-GLUT-1 antibodies. GLUT-IgY antibodies, VEGF165, or both were pre-incubated with
primary astrocytes (A), U87 cells (B), or HeLa cells (C) before infection with pseudotyped HTLV-1. The effect on HTLV-1 infection was examined 48 h post-infection by measuring
luciferase production (RLU). Normal chicken IgY was used as a negative control. The results are from one experiment performed in duplicates and are representative of at least three
different experiments.
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that NP-1 is utilized as a cellular receptor by HTLV-1. First,
recombinant expression of NP-1 but not NP-2 signiﬁcantly increased
the susceptibility of CHO cells to Env-mediated fusion and HTLV-1
infection. Second, siRNA-mediated reduction of NP-1 but not GLUT-1
in U87 cells was associated with a signiﬁcant reduction in HTLV-1
Env-mediated fusion. Third, HTLV-1 infection of U87 cells was
efﬁciently blocked by VEGF165, a high afﬁnity ligand speciﬁc for NP-
1. Finally, FACS analysis demonstrated a high-level expression of cell
surface NP-1 and trace amounts of GLUT-1 on U87 cells. Our results
are consistent with previous data in the literature showing high levels
of NP-1 expression in U87 cells (Rieger et al., 2003).
Previous studies reported that HSPG is the receptor that allows
HTLV-1 to infect CD4+ T lymphocytes (Jones et al., 2005). It is well
known that HSPG enhances attachment by almost all viruses
(reviewed in Manel et al., 2005). The HSPG involvement in this
seems very similar to the role of HSPG in HIV-1 infection; that is,Fig. 7. Co-immunoprecipitation of HTLV-1 Env by antibodies to human NP-1. Primary human
virus encoding the HTLV-1 Env63 were used to prepare cellular lysates for immunoprecipita
PAGE and blotted. The blot was ﬁrst probed with anti-NP-1, stripped, reprobed with anti-gp
right side mark the positions of the different proteins. The positions of the molecular weighpromoting attachment without being involved in the membrane
fusion events. Previous studies have shown that HSPG has promoted
attachment of HIV-1 on macrophages that express low levels of CD4
(Saphire et al., 2001). The current model of HIV-1 entry argues against
the involvement of HSPG in themembrane fusion events that result in
the internalization of HIV-1 virions into the host cell. Nonetheless, the
possible involvement of HSPG can be considered in a broader context
since the internalization of enveloped viruses from many families can
be strongly inﬂuenced by HSPG (Liu and Thorp, 2002; Shukla and
Spear, 2001).
The recent report that DC-SIGN facilitates HTLV-1 entry into
myeloid dendritic cells (Ceccaldi et al., 2006) is also noteworthy in
view of emerging evidence implicating C-type lectins in interactions
of many viruses with the cell surface of target cells (Altmeyer, 2004).
These surface entities play important roles in facilitating the entry of
many viruses, in some cases by serving as attachment factors to
enhance virus adsorption to the cell. In addition, they may participateastrocytes infected with either the WR vaccinia control or with a recombinant vaccinia
tion with Anti-NP-1 antibodies. The precipitated proteins were fractionated in 10% SDS-
46 (anti-Env), stripped, and then re-probed with anti-GLUT-1 antibodies. Arrows at the
t markers are indicated at the left side.
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directly involve the speciﬁc entry mechanism. These considerations
highlight the difﬁculties in deﬁning the molecular elements that
comprise the essential entry machinery and in distinguishing them
from factors that play important accessory roles. The involvement of
HSPGs, GLUT-1, and NP-1 proteins in HTLV-1 entry suggested a
complex method of viral entry. The sequence of the molecular events
involved in HTLV-1 entry is unknown.
NP-1 is a cell surface receptor that has been implicated to function
in the development of both the cardiovascular and nervous systems.
Additionally, NP-1 is involved in regulation of cell migration,
morphogenesis, and membrane protrusions (recently reviewed in
Mendes-da-Cruz et al., 2009). Previous studies demonstrated that
HTLV-1 Env-mediated fusion is enhanced by increased cell adhesion
(Daenke et al., 1999; Hildreth et al., 1997). At the present time, it is not
clear whether increased Env-mediated fusion is merely due to
increased rufﬂing of the plasma membrane or increased cellular
adhesion in NP-1-expressing cells. It is possible that high levels of NP-
1 expression could compensate for the low levels of GLUT-1
expression by increasing the adhesive properties of U87 cells.
The neuropilin genes, NP-1 and NP-2, share similar protein
structure but differ in their expression patterns, regulation, and
ligand-binding speciﬁcities. Human NP-1 and NP-2 show 43% amino
acid homology while human and rat NP-1 show 87% homology
(reviewed in Guttmann-Raviv et al., 2006). The high degree of amino
acid homology between the human and rat NP-1 may explain our
observed positive fusion signal with the rat NP-1. Early studies have
demonstrated that titers of HTLV-1 Env pseudotyped viruses were
nearly always higher on human cells than on rat or murine cell lines
(Sutton and Littman, 1996; Trejo and Ratner, 2000). Additionally, the
observed low levels of GLUT-1 and NP-1 in CHO cells might explain
previous observations that the levels of HSPGs on CHO cells correlate
with the titer of HTLV-1 pseudotyped viruses and other Env-mediated
interactions on those cells (Pinon et al., 2003).
We demonstrated physical interaction between NP-1, GLUT-1,
and HTLV-1 Env in primary human astrocytes. Our results conﬁrm
previous studies showing that GLUT-1 and NP-1 form intracellular
complexes in 293 cells that are increased in the presence of HTLV-1
Env (Ghez et al., 2006). Ghez et al. have demonstrated that NP-1
and GLUT-1 colocalize in membrane junctions formed between
infected and uninfected T cells. Our study demonstrated for the ﬁrst
time the physical association of endogenous NP-1 and GLUT-1 in
primary astrocytes without the presence of HTLV-1 Env (Fig. 7,
Panel C). These results are different from those reported earlier
showing that the co-immunoprecipitation of NP-1 and GLUT-1 was
dependent on the presence of Env in transfected 293 or HeLa cells
(Ghez et al., 2006; Lambert et al., 2009). The different cell type
utilized in the different studies might explain this discrepancy. Our
results were obtained by using primary astrocytes where the levels
of NP-1 and GLUT-1 are different from those in human cell lines.
The usage of both NP-1 and GLUT-1 in primary astrocytes suggests
the possibility of a receptor/coreceptor system utilized by HTLV-1
for speciﬁc entry into the brain. This possibility needs further
investigation.
Ligand-induced downmodulation of cell surface receptors repre-
sents an obvious mechanism by which VEGF165 inhibits HTLV-1
Env-mediated fusion and virus infection. In support of this
conclusion, Narazaki and Tosato have provided strong experimental
evidence for VEGF165-induced internalization of NP-1 in endothelial
cells (Narazaki et al., 2008; Narazaki and Tosato, 2006). Addition-
ally, Lambert et al. (2009) have recently demonstrated that the
VEGF165-homologous region on HTLV-1 Env directly binds NP-1 and
is essential for internalization and infection of CD4+ T cells and
dendritic cells. An alternative mechanism would be direct blocking
of the Env interaction site(s). In view of our results it seems that the
ﬁrst mechanism may be in effect although we cannot disregard themechanism of steric blockade. Recent studies proposed that VEGF165
is a selective competitor of HTLV-1 entry and that the b domain of
NP-1 is required for HTLV-1 binding (Lambert et al., 2009). This is in
agreement with our ﬁnding that VEGF165 blocked HTLV-1 envelope-
mediated entry by a receptor downmodulation mechanism. Binding
of VEGF165 to HSPGs (Krilleke et al., 2007) has previously been
demonstrated, therefore, it cannot be ruled out that at least part of
the observed inhibition by VEGF165 might be due to blocking
interaction with HSPGs. However, as discussed earlier it is hard to
designate a speciﬁc role for HSPGs in the membrane fusion events
or in receptor downmodulation. These results have implications for
designing novel VEGF165 NP-1-targeted therapies for HTLV-1 since
they suggest that an agent capable of both downmodulating NP-1
and physically blocking its interaction with Env may be most
efﬁcacious.
Analysis of the mechanism of HTLV-1 infection of primary
astrocytes is critical for the fundamental understanding of virus–
host interaction and will provide important insight into the
mechanism of HTLV-1 neuro-tropism. The ability to explore the
biochemical basis of Env/GLUT-1/NP-1 interactions in direct binding
assays and the availability of antibodies to study the GLUT-1 and NP-1
proteins at the cellular level will provide important new information
on the role of these molecules in viral infection and their contribution
to tropism and cytopathic effects of retroviral infections.Materials and methods
Cells and viruses
HeLa cells, 293 cells, and CHO cells were obtained from the
American Type Culture Collection. U87 cells were obtained from NIH
AIDS Research & Reference Reagent Program (lot # 4 021998). The
U87 cells were subjected to multiple rounds of cell cloning in the
presence of 10% calf serum supplemented with glial cell medium
with G-5 supplement (Invitrogen Corporation, Grand Island, NY).
Cells were grown in DMEM containing 10% cosmic calf serum (U87)
or 10% fetal bovine serum (293, HeLa and CHO), penicillin G (100
units/ml) and streptomycin sulfate (0.1 mg/ml) in a humidiﬁed
incubator held at 5% CO2. All cell culture media were purchased from
GIBCO. Normal Human Astrocytes (NHA) and their basal medium
(with 10% FBS) were purchased from AllCells (AllCells, LLC, Emery-
ville, CA, Cat#NHA-001F).
The recombinant vaccinia viruses used in the Env-mediated fusion
assay have been previously described (Agrawal et al., 2004a, 2002,
2004b). The Western Reserve (WR) refers to the vaccinia virus empty
vector used to generate all our recombinant viruses. The recombinant
vaccinia virus encoding the HTLV-1 cleavage mutant (Unc63) has
been used as a negative control in the Env-mediated fusion assays (Jin
et al., 2006b). The cleavage site of the HTLV-1 Env at residues 309–312
(RSRR) was changed to GLGL in Unc63. The Unc63 was used as an
envelope control to measure the background fusion since it can bind
target cells but does not engage in cell fusion activity.Human and rat neuropilin 1 cDNA clones
We utilized poly A+ RNA isolated from U87 cells as a template in
an RT-PCR reaction to clone the human NP-1 from U87 cells. We
obtained the rat NP-1 from the laboratory of Dr. David Ginty,
Department of Neuroscience, The Johns Hopkins University School
of Medicine, Baltimore, MD. Human NP-2 cDNA was obtained by RT-
PCR cloning from U373 cells using NP-2 speciﬁc primers and mRNA
isolated from U373 cells. The 3 kb PCR product was cloned into
pCDNA3.1 downstream of T7 and CMV promoters. The cDNA
sequencing conﬁrmed that the cloned fragment encodes human NP-2.
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RT-PCR was performed using freshly isolated total RNA (RNeasy
mini kit, Qiagen) from U87, U373, HeLa, and 293 cells. The cDNA
synthesis was accomplished by using the superscript III ﬁrst-strand
synthesis system that is part of the RT-PCR protocol (Invitrogen).
Approximately, 5 μg RNA was used to synthesize ﬁrst-strand cDNA in
a volume of 20 μl. A 2 μl aliquot of RT product was used as template in
a 25-μl PCR reaction. The PCR conditions were as follows: 35 cycles,
1 min/94 °C, 1 min/annealing temperature, 1–3 min/72 °C. Primer
sequences and annealing temperatures were as follows: NP-1 cDNA
forward primer: 5′-atggagagggggctgccgc-3′ and reverse primer: 5′-
ctcgagttcatctctgtctgccttca-3′, annealing at 60 °C. NP-2 cDNA
forward primer: 5′-atggatatgtttcctctcacctgg-3′ and reverse primer:
5′-tcatgcctcggagcagcacttttg-3′, annealing at 65 °C.
For RT-PCR analysis the primer sequences are the following: the β-
actin forward primer: 5′-gagcacagagcctcgcctttgc-3′ and reverse
primer: 5′- tcttctcgcggttggccttggg-3′, annealing at 55 °C. NP-1 forward
primer: 5′-atggagagggggctgccg-3′ and reverse primer: 5′-caacatcagg-
gaatccatccc-3′ annealing at 57 °C. Glut-1 forward primer: 5′-atggagc-
ccagcagcaagaa-3′ and reverse primer: 5′-agggaccagagcgtggtgag-3′
annealing at 57 °C. Glut-3 forward primer: 5′-atggggacacagaaggtcac-
3′ and reverse primer: 5′-acagacaaggaccagagaga-3′ annealing at
55 °C.
HTLV-1 Env-mediated fusion and VEGF165 blocking experiments
Env-mediated cell fusion was measured by a vaccinia-based
reporter gene assay (Jin et al., 2006b). The assay analyzes fusion
between two distinct cell populations, one that expresses the
potential receptor along with the lacZ gene linked to the T7 promoter
and another that expresses HTLV-1 Env and T7 RNA polymerase
encoded by a recombinant vaccinia virus. All cell populations were
incubated overnight at 31 °C to allow expression of the vaccinia-
encoded proteins. Duplicate samples containing 105 target cells and
the same number of effector cells were mixed in 96 well micro-titer
plates and incubated at 37 °C for 2.5 h. The extent of Env-mediated
fusion was assayed by colorimetric measurement of β-galactosidase
activity in detergent-treated cell lysates (Nussbaum et al., 1994). For
blocking experiments, recombinant human VEGF165 (PeproTech, Inc,
Rocky Hill, NJ, Cat#100-20) at increasing concentrations (0, 10, 100,
500 ng/ml) was added to the target cells (105 HeLa or U87 cells). The
cells and VEGF165 mixture was incubated for 30 min at 37 °C. The cell
mixture was then mixed with the corresponding Env-expressing cell
population and incubated at 37 °C for 2.5 h. The blocking effect was
evaluated by a colorimetric measurement of β-glycosidase produced
as a result of cell fusion. Control wells incubated with irrelevant
bacterial proteins were included.
SiRNA experiments
We purchased the human neuropilin siRNA molecules from
Santa Cruz Biotechnology, Inc., CA (Cat# sc-36038). The Glut-1
siRNA was purchased from Integrated DNA Technologies (Coralville,
IA) and used as previously described (Jin et al., 2006a, 2006b).
Brieﬂy, U87 cells were plated at 1.5×105 cells/well in a six-well
plate using serum-free medium without antibiotics. The siRNA
(10 nM) was transfected by oligofectamine reagent (Invitrogen,
Cat#12252-011). After a 4 h incubation period at 37 °C, the cells
were washed and changed with fresh media containing 10% FBS.
Following incubation for 72 h in a 37 °C incubator the transfected
cells were infected with pT7-lacZ reporter. Separate populations of
293 cells were infected with vaccinia viruses encoding T7 RNA
polymerase and either the wild type HTLV-1 envelope glycoprotein
(Env63) or the uncleaved HTLV-1 Env (Unc63). At 16 h post-
infection the Env-expressing cells were mixed (1:1) with the siRNA-transfected cells and incubated for 2.5 h to allow cell fusion. The
effect of siRNA on Env-mediated fusion was assayed by measuring
β-galactosidase produced. The negative and positive control siRNA
were also purchased from Integrated DNA Technologies.
Pseudotyped virus infection
We adapted the improved pseudotyping assay developed by
Sutton and Littman (1996) to prepare pseudotyped virus particles
that carry the HTLV-1 Env protein. 293T cells were cotransfected with
10 μg of PcREV and 10 μg of the envelope-defective luciferase
transducing HIV proviral clone pNL4-3. Luc+env- (Catalog # 3418,
AIDS Reagent Program) in the presence or absence of 10 μg of pHTLV-
env-rre using standard calcium phosphate. Fifteen hours following
transfection, 20 mM sodium butyrate and fresh media were added.
The supernatants were harvested after 48–72 h by low-speed
centrifugation and ﬁltrated through a 0.22 µm ﬁlter. Pseudotyped
vesicular stomatitis virus G glycoprotein (VSV-G) was used as a
positive control to verify the competence of all cell types in cell fusion.
HTLV-1 infection assays were performed by incubating 3×105
cells/ml containing 5 μg/ml polybrene mixed with 1 ml of
pseudotyped HTLV-1 virus stock and plated into the wells of a six-
well plate. The mixture was incubated for 4–5 h at 37 °C in a 5% CO2
incubator. Following incubation the cells were washed with 10% FBS,
fresh medium was added and incubation continued for another 48 h.
The cells were harvested and luciferase assay was performed using
the luciferase assay system as recommended by the manufacturer
(Promega, Madison, WI).
Cell surface expression of receptors and protein analysis
To detect GLUT-1 at the cell surface, we used previously described
chicken polyclonal antibodies generated against a synthetic peptide
corresponding to the large extracellular domain of GLUT-1 (ECL1)
(Agrawal et al., 2006).Wewill refer to these antibodies as GLUT-IgY to
indicate the source of these antibodies. Other antibodies used for cell
surface staining of GLUT-1 were mouse monoclonal anti-human Glut-
1, Glut-3 (Alpha Diagnostic International, Inc, San Antonio, TX,
Cat#GT15-M and Cat#GT-34-M). For VEGF165-induced downmodula-
tion we used the mouse anti-human BDCA-4 (neuropilin-1) mono-
clonal antibody (Miltenyi Biotec, Cat#130-090-533), and monoclonal
anti-rat neuropilin-1 antibody (R&D System, Cat#AF566). The U87
cells were incubated with the VEGF165, washed with cold PBS
containing 0.1% PBS/BSA, pelleted by centrifugation for 5 min at
500×g at 4 °C. After ﬁxing with 4% formaldehyde, the cells, either
permeabilized (0.05% Saponin for 15 min on ice) or non-permeabi-
lized, were resuspended in 100 μl of 1% PBS/BSA containing a 1:1000
diluted chicken anti-human GLUT-IgY antibody or a mouse monoclo-
nal antibody at a concentration of 10 μg/ml. The mixtures were then
incubated on ice for 30 min. The cells were then washed with 1% PBS/
BSA, pelleted, and resuspended in 100 μl of 1% PBS/BSA containing
2 μg of FITC-conjugated rabbit anti-chicken IgY (Biomeda, Foster City,
CA) or FITC-conjugated rat anti-mouse IgG1 (A85-1, BD Biosciences
Pharmingen). The cells were then incubated on ice for 30min, washed
three times with 1% PBS/BSA solution, and resuspended in 1ml of PBS
and analyzed in a FACS Vantage ﬂow cytometer (Becton-Dickinson,
San Jose, CA).
Immunoblot analysis was performed using rabbit antibodies
raised against the C-terminal domain of GLUT-1 (Dakocytomation,
Carpinteria, CA). Rabbit polyclonal anti-human neuropilin antibo-
dies (H-286) were purchased from Santa Cruz Biotechnology, Inc.
(Cat#sc-5541). Dr. Steven Foung provided the human monoclonal
antibody to HTLV-1. The mouse monoclonal antibody to Glyceral-
dehyde-3-PDH (GAPDH) was purchased from Biodesign Interna-
tional, Portland, ME (Cat#H86504M). Cells were rinsed with PBS,
scraped on ice in PBS and centrifuged at 500×g. The cell pellets
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Tris–HCl pH 7.6, 0.1% SDS, Aprotonin 10 µg/ml, PMSF 1 mM) and
incubated for 30 min on ice then sonicated for 1 min to shear the
genomic DNA. After centrifugation, the supernatants were mixed
with same volume of protein loading buffer and fractionated in a
12% SDS-PAGE (0.1×106 cells/lane) and transferred into PVDF
membrane blots. Blots were incubated with rabbit antibodies
directed against C-terminal domain (1:2000) and left rocking
overnight at 4 °C. The blots were developed by BM Chemilumines-
cence using peroxidase-conjugated antibody against mouse/rabbit
IgG (Roche, Indianapolis, IN).
For cell membrane preparations, cells were homogenized in
10 mM Tris, 1 mM EDTA, 1 mM phenlmethylsulphonyl ﬂuoride
(PMSF) and 250 mM sucrose, pH 7.4, in Potter-Elvehjem glass-Teﬂon
type homogenizer at 4 °C. The homogenates were centrifuged at
900×g for 10 min to sediment the fraction containing nuclei and the
supernatants were centrifuged at 17,000×g for 75 min at 4 °C. The
pellets were subjected to 12% SDS-PAGE. An equivalent of 0.1×106
cells were loaded per lane.
Co-immunoprecipitation
Human astrocytes were infected with either an empty WR
vaccinia vector or a recombinant vaccinia virus expressing the
HTLV-1 envelope glycoprotein (gp63) at 10 pfu/cell for 1 h then
incubated overnight at 31 °C. After washing three times with PBS,
the cells were pelleted by centrifuging and suspended in lysis buffer
[300 mMNaCl, 50 mM Tris–HCl pH 7.6, 0.1% SDS, Aprotonin 10 µg/ml,
PMSF 1 mM, and protease inhibitors] at 4 °C for 40 min with gentle
mixing. The protease inhibitors were purchased from Roche
(Complete Mini, Cat#11 836 153 001). The nuclei were pelleted
by centrifugation at 17,000× g for 25 min in a refrigerated
Eppendorf centrifuge. Immobilized Protein A beads (Pierce, Rock-
ford, IL), pre-washed with PBS, were added to the immunoprecipi-
tating antibody (neuropilin A-12, 2 µg/ml) and incubated at 4 °C for
2 h. The Protein A beads and antibody mixture was then added to
the cell lysates and incubated at 4 °C for 16 h. The beads were then
washed four times with 1 ml of ice-cold lysis buffer and eluted by
adding 2×laemmli buffer (Sigma, St. Louis, MO). They were run on
12% SDS-PAGE without boiling for Glut-1 detection and were
electrophoretically transferred to PVDF membranes. The membranes
were blocked with 20 mM Tris–HCl (pH 7.6) buffer containing
140 mM NaCl, 0.1% Tween-20, and 5% nonfat powered milk and
incubated with their respective antibodies. The membranes were
washed and reacted with horseradish peroxidase-conjugated sec-
ondary antibodies and developed by using the supersignal chemi-
luminescent substrate (Pierce).
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